Ó Springer-Verlag 2007 Dear Editor,
We thank the reader for the extensive statement and comments in response to our recent article on the effects of nasal salmon calcitonin in the treatment of lumbar spinal stenosis.
We entirely agree that non-operative measures would be particularly useful in this group of patients who are likely to have multiple medical co-morbidities and are high risk candidates for major surgical interventions. During our study it was clearly evident that there was a very minimal response to treatment with nasal salmon calcitonin, despite an initial randomised placebo controlled phase and a second phase in which all patients received active nasal spray. The author of the letter needs to be aware of the difference between a clinically significant change and a statistically significant change. To be clinically significant a change of 20 mm on VAS is probably required. The study could be repeated at higher dose and longer duration of treatment, but in the absence of funding we are unable to do this. We had to fund the production of placebo ourselves at a cost of 1,100 euros.
A clinically useful methodology to assess efficacy is numbers needed to treat (NNT); in this study 20 patients required treatment to produce one excellent result. That is a NNT of 20. Clinicians can decide for themselves whether this is likely to assist the individual patient in front of them.
Salmon calcitonin may actually work through a direct analgesic effect, which has been suggested by previous reports investigating the effect of calcitonin on pain. This mechanism may have led to the marginal improvement in back pain in the calcitonin group in our study, but again this is not consistent with the associated deterioration in leg pain that occurred at the end of the trial. Another possible explanation is that this result may have occurred by chance due to the multiple statistical tests that were carried out in the study.
The possibility that a type 2 error occurred in our study was discussed in the paper. We do agree that it might be useful to measure levels of calcitonin in the blood following nasal administration of the drug to ensure adequate delivery of the drug. The previous studies that have suggested a beneficial effect of intramuscular and subcutaneous administration of salmon calcitonin in lumbar spinal stenosis did not demonstrate a clinically significant change, simply a statistical difference. In our unit we will be exploring the use of more effective treatments in the future, as patient distress at delay in effective symptom control is increased by non-effective treatment.
